Edition:
United States

Corbus Pharmaceuticals Holdings Inc (CRBP.OQ)

CRBP.OQ on NASDAQ Stock Exchange Global Market

5.90USD
4:00pm EDT
Change (% chg)

$0.10 (+1.72%)
Prev Close
$5.80
Open
$5.80
Day's High
$6.00
Day's Low
$5.72
Volume
378,334
Avg. Vol
103,361
52-wk High
$9.85
52-wk Low
$5.05

Chart for

About

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare... (more)

Overall

Beta: 2.09
Market Cap(Mil.): $342.86
Shares Outstanding(Mil.): 57.14
Dividend: --
Yield (%): --

Financials

  CRBP.OQ Industry Sector
P/E (TTM): -- 244.60 33.54
EPS (TTM): -0.69 -- --
ROI: -66.33 -5.33 13.09
ROE: -67.17 -6.88 15.10

BRIEF-Corbus Pharmaceuticals Reports Q1 Loss Per Share $0.21

* CORBUS PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 10 2018

BRIEF-Corbus Pharmaceuticals Reports 2017 Financial Results And Provides Clinical Update

* CORBUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATE

Mar 12 2018

BRIEF-Corbus Pharmaceuticals Receives $25 Mln Development Award From The Cystic Fibrosis Foundation

* CORBUS PHARMACEUTICALS RECEIVES $25 MILLION DEVELOPMENT AWARD FROM THE CYSTIC FIBROSIS FOUNDATION TO SUPPORT PHASE 2B CLINICAL STUDY OF LENABASUM Source text for Eikon: Further company coverage:

Jan 30 2018

BRIEF-Corbus Agrees With FDA On Phase 2B Cystic Fibrosis Study Design With Pulmonary Exacerbations As Sole Primary Endpoint

* CORBUS PHARMACEUTICALS ANNOUNCES AGREEMENT WITH FDA ON PHASE 2B CYSTIC FIBROSIS STUDY DESIGN WITH PULMONARY EXACERBATIONS AS SOLE PRIMARY ENDPOINT

Jan 29 2018

Corbus cystic fibrosis drug to get FDA review on flare-up data

Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.

Jan 29 2018

Corbus cystic fibrosis drug to get U.S. FDA review on flare-up data

Jan 29 Corbus Pharmaceuticals Holdings Inc said on Monday the U.S. Food and Drug Administration will evaluate its experimental cystic fibrosis drug without requiring proof the product improves lung function, dramatically cutting the time and cost it will take Corbus to develop the drug.

Jan 29 2018

BRIEF-Corbus Pharmaceuticals Files For Mixed Shelf Of Up To $200 Mln ‍​

* CORBUS PHARMACEUTICALS HOLDINGS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING ‍​ Source text: (http://bit.ly/2EciBBu) Further company coverage:

Jan 05 2018

Competitors

Earnings vs. Estimates